19:55 , Nov 8, 2018 |  BC Innovations  |  Emerging Company Profile

Abarceo: restoring beta cell function

Abarceo Pharma AB has identified VDAC1 as a key target in Type II diabetes, and is developing antibodies and small molecule inhibitors against the target as durable and disease-modifying treatments. Standard first-line therapy for Type...
17:38 , Sep 21, 2018 |  BC Week In Review  |  Company News

CRISPR partners with ViaCyte to develop immune-evasive pancreatic cells

CRISPR Therapeutics AG (NASDAQ:CRSP) and ViaCyte Inc. (San Diego, Calif.) partnered to develop a gene edited immune-evasive pancreatic stem cell line as an islet cell replacement therapy that would not require immunosuppression and could potentially...
21:29 , Sep 17, 2018 |  BC Extra  |  Company News

CRISPR partners with ViaCyte to develop immune-evasive pancreatic cells

CRISPR Therapeutics AG (NASDAQ:CRSP) and ViaCyte Inc. (San Diego, Calif.) partnered to develop a gene edited immune-evasive pancreatic stem cell line as an islet cell replacement therapy that would not require immunosuppression and could potentially...
14:48 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Zafgen's ZGN-1061 meets in Phase II for Type II diabetes

Zafgen Inc. (NASDAQ:ZFGN) said the 0.9 mg dose of subcutaneous ZGN-1061 every three days met the primary endpoint in a Phase II trial to treat Type II diabetes in patients failing multiple other antidiabetic agents....
18:08 , May 11, 2018 |  BC Week In Review  |  Financial News

Provention plans IPO, reveals MacroGenics deal

Autoimmune and infectious disease company Provention Bio Inc. (Lebanon, N.J.) proposed on May 9 to raise up to $50 million in an IPO underwritten by MDB Capital Group. The company's pipeline includes several candidates in-licensed...
17:20 , May 11, 2018 |  BC Week In Review  |  Clinical News

Hua's dorzagliatin reduces HbA1c in Phase II for Type II diabetes

Hua Medicine Ltd. (Shanghai, China) reported data from a double-blind, Chinese Phase II trial in 258 Type II diabetics showing that twice-daily 50 and 75 mg doses of oral dorzagliatin (sinogliatin, HMS5552, RO5305552) both significantly...
20:14 , May 10, 2018 |  BC Extra  |  Financial News

Provention plans IPO, reveals MacroGenics deal

Autoimmune and infectious disease company Provention Bio Inc. (Lebanon, N.J.) proposed to raise up to $50 million in an IPO underwritten by MDB Capital Group. The company's pipeline includes several candidates in-licensed from other companies...
00:15 , Mar 10, 2018 |  BC Extra  |  Preclinical News

Increasing ZMPSTE24 could help treat, prevent Type II diabetes

A study published in Cell showed that the yeast homolog of zinc metallopeptidase STE24 (ZMPSTE24) reduced islet amyloid polypeptide (IAPP) oligomer-induced proteotoxicity by declogging aggregates found in pancreatic beta cells, suggesting that increasing ZMPSTE24 could...
16:37 , Dec 15, 2017 |  BC Week In Review  |  Company News

reMYND out-licenses diabetes candidate to Novo

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) gained exclusive, worldwide rights from reMYND N.V. (Leuven, Belgium) to develop and commercialize ReS39, which reMYND believes has the potential to be a disease-modifying treatment for diabetes. reMYND received an...
06:33 , Dec 14, 2017 |  BC Extra  |  Company News

reMYND out-licenses diabetes candidate to Novo

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) gained exclusive, worldwide rights from reMYND N.V. (Leuven, Belgium) to develop and commercialize ReS39, which reMYND believes has the potential to be a disease-modifying treatment for diabetes. reMYND received an...